Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Multienzyme complexes or mixtures of enzymes
Patent
1991-05-30
1992-05-26
Stone, Jacqueline
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Multienzyme complexes or mixtures of enzymes
424 9421, 424 946, 424 9461, 424 9462, 424 9463, 424 9464, 424 9465, 424 9467, A61K 3762, A61K 37547, A61K 3754, A61K
Patent
active
051166151
ABSTRACT:
The invention provides a composition and method for treating benign prostatic hypertropy in mammals so as to cause the dissolution and regression of hypertrophied prostatic tissue and thereby provide relief from the obstructive symptoms associated with the disease. The present composition preferably comprises a sterile pyrogen-free solution of the hydrolytic enzymes collagenase and hyaluronidase, a nonionic surfactant, and an antibiotic; all provided, in a pharmaceutically acceptable, buffered, isotonic, aqueous carrier. The present method preferably comprises the direct intraprostatic injection of a safe and therapeutically effective dose of the composition via the transurethral route of administration.
REFERENCES:
patent: 3678158 (1972-07-01), Sussman
patent: 3691090 (1972-09-01), Kitajima et al.
patent: 3792161 (1974-02-01), Fox
patent: 3977408 (1976-08-01), MacKew
patent: 4005194 (1977-01-01), Johnson
patent: 4174389 (1979-11-01), Cope
patent: 4224179 (1980-09-01), Schneider
patent: 4224313 (1980-09-01), Zimmerman et al.
patent: 4276281 (1981-06-01), Crikelair
patent: 4276284 (1981-06-01), Brown
patent: 4310523 (1982-01-01), Neumann
patent: 4317817 (1982-03-01), Blohm
patent: 4317818 (1982-03-01), Benson et al.
patent: 4338300 (1982-07-01), Gelbard
patent: 4440749 (1984-04-01), Fujisaki et al.
patent: 4446129 (1984-05-01), Sawada
patent: 4485095 (1984-11-01), Fujisaki et al.
patent: 4524065 (1985-06-01), Pinnell
J. T. Grayhack et al. in Benign Prostatic Hyperplasia; J. T. Grayhack, J. D. Scherbenske, Eds.; DHEW Publication No. (NIH 76-113); Bethesda, MD, 1975, p. 125, disclose the results of surgical treatment of BPH.
T. C. Ingl et al., J. Urol., 137, 1189 (1987), disclose the results of surgical treatment of BPH.
J. T. Grayhack et al., in Adult and Pediatric Urology, J. T. Grayhack, Y. J. Gillenwater, Eds.; Yearbook Medical Press: Chicago, IL, 1987; vol. 2; p. 1062, disclose general information about BPH including medical treatment (see p. 1089).
S. Boyarsky in Benign Prostatic Hypertrophy; F. Hinman, Ed.; Springer-Verlag; New York, NY, 1983, p. 425, discloses certain pharacologic treatments of BPH.
A. Yerushalmi et al., J. Urol., 133, 873 (1985) disclose localized deep microwave hyperthermia in the treatment of BPH.
M. G. McLouglin et al. in Benign Prostatic Hypertrophy; F. Hinman, Ed.; Springer-Verlag: New York, NY, 1983; p. 130, disclose a study of the stromal-epithelial interaction in BPH.
W. W. Scott et al. in Benign Prostatic Hyperplasia; J. T. Grayback, J. D. Wilson, M. J. Scherbenske, Eds.; DHEW Publication No. (NIH 76-1113); Bethesda, MD, 1975, p. 135, disclose methods used to shrink the modular hyperplasia mass by hormonal manipulations.
G. Williams in Endocrinology of Prostate Tumors; R. Ghanadian, Ed.; MTP Press: Boston, MA, 1983; p. 263, discloses the response of BPH to endocrine therapy and hormonal therapy.
P. C. Walsh in Campbell's Urology; P. C. Walsh, R. F. Gittes, Eds.; W. B. Saunders: Philadelphia, PA, 1986; vol. 2; p. 1248, disclosed general information about BPH including treatment methods (see p. 1261).
A. Sjoerdsma, Clin. Pharmacol. Ther., 30, (1981) discloses the use of suicide enzyme inhibitors in the treatment of BPH.
N. Sonino, N. Engl. J. Med., 317, 812 (1987) disclosed the use of ketoconazole as an inhibitor of steroid production.
C. A. Peters et al., N. Engl. J. Med., 317, 599 (1987) disclose the use of nafarelin acetate, a luteinizing-hormone releasing hormone agonist in the treatment of BPH.
M. Caine, Seminars in Urology, 3, 311 (1985) discloses the use of a A-adrenergic blocking agents in the treatment of BPH.
C. P. Schaffner in Process of Clinical and Biological Research; G. P. Murphy, Ed.; A. R. Liss: New York, NY, 1981; vol. 75A; p. 294, discussed hypocholesterolemic agents and the prostate gland.
A. Choudhury et al., British Journal of Urology, 52, 204 (1980) disclose the use of intraprostatic phenol injections in the treatment of BPH.
W. E. Stamm et al. in Harrison's Principles of Internal Medicine; G. R. Petersdorf, Ed.; McGraw Hill: New York, NY, 1983; p. 1649, disclose general information about urinary tract infections, including prostatitis.
D. S. Coffey in Campbell's Urology; P. C. Walsh, R. F. Gittes, Eds.; W. B. Saunders: Philadelphia, PA, 1986; vol. 1; p. 233, discloses the general biochemistry and physiology of the prostate and seminal vesicles.
M. Charton et al., J. Urol., 138, 87 (1987) disclose a study of antibiotic prophylaxis of urinary tract infections after transurethral resection of the prostate.
E. W. Ramsey et al., Urology, 21, 376 (1983) disclose antibiotic prophylaxis of urinary tract infections after transurethral resection of the prostate.
M. Bhargava et al., Indian J. Exp. Biol., 15, 762 (1977) disclose histopathological changes due to injection therapy of an enlarged prostate.
S. C. Kabra et al. in Indian J. Exp. Biol., 15, 768 (1977) disclose the fate of fluid injected during injection therapy of an enlarged prostate.
J. Jhanwar et al., Indian J. Exp. Biol., 15, 772 (1977) disclose injection of a carbolic acid-acetic acid-glycerine mixture and its effect on an enlarged prostate.
C. H. J. Ford et al., Cancer Chemother. Pharmacol., 17, 197 (1986) disclose a review of antibody-mediated targeting in the treatment and diagnosis of cancer.
L. Baert et al., Urology, 21, 370 (1983) disclose the treatment of chronic bacterial prostatitis by local injection of antibiotics into prostate.
E. M. Meares, Jr. in Campbell's Urology; P. C. Walsh, R. F. Gittes, Eds.; W. B. Saunders: Philadelphia, PA, 1986; vol. 1; p. 868, discloses general background information on prostatitis and related disorders.
M. I. Resnick in Benign Prostatic Hyperplasia; J. T. Grayhack, J. D. Wilson, M. J. Scherbenske, Eds.; PHEW Publication No. (NIH 76-1113); Bethesda, MD, 1975; p. 249, discusses various techniques of prostatic perfusion used in BPH experimental treatment.
I. Mandl in Collagenase; I. Mandi; Gordon & Breach: New York, NY, 1972; p. 1, discloses general information about, and various uses of, collagenase.
M. M. Webber, In Vitro, 15, 967 (1979) discloses the use of collagenase for tissue dissociation in the isolation of normal and benign human prostatic epithelium in vitro.
A. M. Boxer et al. in Collagenase; I. Mandl, Ed.; Gordon & Breach: New York, NY, 1972; p. 155, discloses the use of collagenase in the debridement of burns and ulcers.
M. M. Levi in Collagenase; I. Mandl, Ed.; Gordon & Breach: New York, NY, 1972, p. 197, disclosed the use of collagenase in gynecology.
F. W. Longo et al. in Collagenase; I. Mandl, Ed.; Gordon & Breach: New York, NY, 1972; p. 113, disclose the use of collagenase in the dissolution of "cyroslough following cryogenic surgery".
B. J. Sussman et al., in Collagenase; I. Mandl, Ed.; Gordon & Breach: New York, NY, 1972; p. 101, disclose the effect of collagenase on intervertebral discolysis.
T. E. Cawston et al. in Methods in Enzymology; L. Lorand, Ed.; Academic Press: New York, NY 1981; vol. 80; p. 711, disclose general information on mammalian collagenase.
E. Wunsch et al., Z. Phisiol. Chem., 333, 149 (1963) disclose a new specific and rapid determination of collagenase.
Pharmaceutical Enzymes Properties and Assay Methods, R. Ruyssen et al., Ed.; E. Story-Scientia: Gent, Belgium, 1978; disclose general information about hyaluronidase and its therapeutic use.
P. R. Maroko et al., N. Engl. J. Med., 296, 898 (1977) disclose the effects of hyaluronidase in reducing post-infarction myocardial necrosis
A. Linker in Methods of Enzymatic Analysis; H. H. Bergmeyer, Ed.; Verlag Chemie: Deerfield Beach, FL, 1983; vol. 4; p. 256, discloses a method of analyzing hyaluronidase.
A. Abuchowski et al., Biochim, Biophys. Acta, 578, 41 (1978) disclose polyethylene glycol modified trypsin.
K. V. Savoca et al., Biochim. Biophys. Acta, 578, 47 (1979) disclose polyethylene glycol modified arginase.
G. L. Moore, Anal. Biochem., 32, 122 (1969) discloses a method of measuring the activity of proteolytic enzymes.
Biomedical Information, J. Kessey, Ed.; Bolhringer Mannheim; Indianapolis, IN, 1987; 1st Ed.; p. 197, discloses information
Gokcen Muharrem
Guy Terry J.
Immunolytics Inc.
Stone Jacqueline
LandOfFree
Method for treating benign prostatic hypertrophy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating benign prostatic hypertrophy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating benign prostatic hypertrophy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-418213